Psoriatic Arthritis - Clinical Study [US,CA] (Email,Social,Banner,Native,Push,SEO,Search,Brand Bidding) - CPL

RESTRICTIONS

Conversion Point: Valid Form Fill Ages: 18+ Gender: Any GEO: US Only Traffic Allowed: Email, Social, Banner, Native, Push, SEO, Search, Brand Bidding No Incent No Co-Reg No Survey No SMS No Adult Send ad creatives and LP to AM for approval Forbidden traffic types/false Advertisements Will NOT Be Paid For Fake/false celebrity ads/endorsements are strictly prohibited Qualifications: - Have you been diagnosed with psoriatic arthritis (PsA) for 3 months or longer (answer: Yes) - Do you have active plaque psoriasis lesions or a history of plaque psoriasis (answer: Yes) - Have you ever taken medication to treat your PsA? (includes current and past use) (answer: Yes) - Have you ever taken a TNF-alpha inhibitor to treat your PsA? Examples include: - Cimzia (certolizumab) Enbrel (etanercept) Humira (adalimumab) Remicade (infliximab) Simponi (golimumab) (answer: yes or unsure) - Have you been diagnosed with any of the following conditions? - Lupus - Multiple Sclerosis - Rheumatoid Arthritis - Gout - Lyme disease (answer: No) Study Description: The purpose of this clinical study is to see how effective an investigational medication is at helping to treat psoriatic arthritis. You may be asked to attend a screening visit to determine if you are eligible to enroll in the study. If enrolled, you will receive either the study medication, a placebo, or an FDA-approved medication (apremilast) to be taken twice daily for four months. After four months, participants receiving the placebo option will be re-assigned to the study drug or apremilast and all participants will continue taking their medication for an additional 8 months. Your total participation will last approximately 14 months and will include regular doctor’s visits for follow-up care and testing. After the initial treatment portion of the study, there will be an opportunity for participants to join an optional open label extension period where they will take the investigational study drug for an additional 2 years. The doctor’s office conducting the study will be able to provide you with more information about the study requirements and the optional open label extension period. Participants who qualify for the study will receive trial-related procedures and study medication (or placebo) at no cost and may be compensated for time and travel.